Spruce Biosciences
Filed with the SEC on · accession 0001193125-26-452714
SPRB filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. Spruce Biosciences filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing details of its Avenue loan agreement, warrants, and equity financings. The stock moved +6.0% by the first close after the filing.
Spruce Biosciences filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing details of its Avenue loan agreement, warrants, and equity financings. The filing includes routine financial statements and subsequent event disclosures.
Close before
$46.55
Nov 6, 2026
First close after
+5.99%
$49.34
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SPRB, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SPRB?
Click hereSPRB filed a 10-Q (SEC filing). Spruce Biosciences filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing details of its Avenue loan agreement, warrants, and equity financings. The filing includes routine financial statements and subsequent event disclosures.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
SPRB closed at $46.55 before the filing and $49.34 on Nov 9, 2026 (+5.99%).
Get alerts when SPRB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days